ADMA BIOLOGICS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
ADMA BIOLOGICS, INC. (ADMA) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2024-02-28
- ADMA BIOLOGICS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ADMA BIOLOGICS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $211.00K, a 12.08% decline from fiscal 2021.
- ADMA BIOLOGICS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2021 was $240.00K, a 2.83% decline from fiscal 2020.
- ADMA BIOLOGICS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2020 was $246.99K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month as first filed |
|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-28 | |
| 2022-12-31 | $211.00K 10-K · filed 2024-02-28 | $211.34K 10-K · filed 2023-03-23 |
| 2021-12-31 | $240.00K 10-K · filed 2024-02-28 | $239.59K 10-K · filed 2022-03-24 |
| 2020-12-31 | $246.99K 10-K · filed 2022-03-24 | -$246.99K 10-K · filed 2021-03-25 |
| 2019-12-31 | -$115.09K 10-K · filed 2021-03-25 | |
| 2018-12-31 | -$223.74K 10-K · filed 2020-03-13 | |
| 2017-12-31 | -$272.26K 10-K · filed 2019-03-13 | |
| 2016-12-31 | -$322.50K 10-K · filed 2018-03-29 | |
| 2015-12-31 | -$389.36K 10-K · filed 2017-02-24 | |
| 2014-12-31 | -$551.86K 10-K · filed 2016-03-23 | |
| 2013-12-31 | -$599.00K 10-K · filed 2015-03-09 | |
| 2012-12-31 | $0.00 10-K · filed 2014-03-28 | |
| 2011-12-31 | -$97.01K 10-K · filed 2013-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |